Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Britain Courts Anthropic Amid US Defense Department Dispute 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
WALTHAM, Mass., June 29, 2017 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to support the Ovarian Cancer Research Fund Alliance (OCRFA) as the Presenting Sponsor of the 2017 Ovarian Cancer National Conference, being held July 7-9 in Chicago, IL. The OCRFA National Conference is the largest and longest-running conference for women living with ovarian cancer and their caregivers, bringing together more than 400 survivors, caregivers, researchers, and advocates to hear about the latest innovations in ovarian cancer, find hope and inspiration, and support ovarian cancer awareness initiatives.
“Our annual conference is an opportunity to provide much needed education on cutting-edge developments in diagnosis, treatment and quality of life to women with ovarian cancer and their caregivers,” said Audra Moran, President & CEO of Ovarian Cancer Research Fund Alliance. “We are excited to partner with TESARO on our flagship conference and look forward to continued collaboration in the future.”
“Driven by a deep appreciation for patient needs, TESARO is committed to not only supporting, but truly partnering with women living with ovarian cancer,” said Lonnie Moulder, CEO of TESARO. “Patients are at the center of all that we do, and we are thrilled to join forces with OCRFA to support the 2017 Ovarian Cancer National Conference and be a part of this life-changing experience for survivors and caregivers.”
For more information about the Ovarian Cancer National Conference, please visit https://conference.ocrfa.org.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
Investor/Media Contact: Jennifer Davis Vice President, Corporate Affairs & Investor Relations +1.781.325.1116 or [email protected]
